Medindia
Medindia LOGIN REGISTER
Advertisement

Perrigo Company Announces Launch of Clobetasol Propionate Foam

Friday, March 21, 2008 General News
Advertisement
ALLEGAN, Mich., March 20 Perrigo Company(Nasdaq: PRGO; TASE) today announced that the United States District Court forthe District of New Jersey has denied Connetics Corporation's motion for apreliminary injunction related to Perrigo's Clobetasol Propionate Foam, theAB-rated generic equivalent to Connetics' Olux(R) Foam and has lifted thetemporary restraints that have prevented Perrigo from launching the product.The Court also denied Perrigo's motion for Summary Judgment based on non-infringement. The case will now proceed to trial with the trial date nothaving been set.
Advertisement

With the temporary restraints lifted, Perrigo has commenced launching theproduct. As the first filer, this commences its 180 days of genericexclusivity.
Advertisement

Perrigo's Chairman and CEO Joseph C. Papa stated, "We are excited aboutthe launch of Clobetasol Foam, which reflects our on-going efforts to makequality healthcare more affordable for our customers."

Clobetasol Propionate Foam is a topical corticosteroid indicated for thetreatment of moderate to severe dermatosis of the scalp. Sales for the brand,Olux(R) Foam, 0.05%, were approximately $85 million according to WoltersKluwer data for the 12 months ending January 2008.

Perrigo Company is a leading global healthcare supplier that develops,manufactures and distributes over-the-counter (OTC) and prescriptionpharmaceuticals, nutritional products, active pharmaceutical ingredients (API)and consumer products. The Company is the world's largest manufacturer of OTCpharmaceutical products for the store brand market. The Company's primarymarkets and locations of manufacturing facilities are the United States,Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet(http://www.perrigo.com ).

Note: Certain statements in this press release are forward-lookingstatements within the meaning of Section 21E of the Securities Exchange Act of1934, as amended, and are subject to the safe harbor created thereby. Thesestatements relate to future events or the Company's future financialperformance and involve known and unknown risks, uncertainties and otherfactors that may cause the actual results, levels of activity, performance orachievements of the Company or its industry to be materially different fromthose expressed or implied by any forward-looking statements. In some cases,forward-looking statements can be identified by terminology such as "may,""will," "could," "would," "should," "expect," "plan," "anticipate," "intend,""believe," "estimate," "predict," "potential" or other comparable terminology.The Company has based these forward-looking statements on its currentexpectations, assumptions, estimates and projections. While the Companybelieves these expectations, assumptions, estimates and projections arereasonable, such forward-looking statements are only predictions and involveknown and unknown risks and uncertainties, many of which are beyond theCompany's control. These and other important factors, including thosediscussed under "Risk Factors" in the Company's Form 10-K for the year endedJune 30, 2007, as well as the Company's subsequent filings with the Securitiesand Exchange Commission, may cause actual results, performance or achievementsto differ materially from those expressed or implied by these forward-lookingstatements. The forward-looking statements in this press release are madeonly as of the date hereof, and unless otherwise required by applicablesecurities laws, the Company disclaims any intention or obligation to updateor revise any forward-looking statements, whether as a result of newinformation, future events or otherwise.

SOURCE Perrigo Company
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close